Camptothecins for drug design, Cancer cell death and gene targeting

Cancer Drug Design and Discovery

Volumn , Issue , 2008, Pages 173-197

  Kluza, Jérôme ^a   Arimondo, Paola B ^b   David Cordonnier, Marie Hélène ^a   Bailly, Christian ^a  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950865180     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369448-5.50011-2     Document Type: Chapter

References (189)

1. Abedin M.J., Wang D., McDonnell M.A., et al. Autophagy delays apoptotic death in breast Cancer cells following DNA damage. Cell Death. Diff. 2006, 14:500-510.
2. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic Cancer. J. Clin. Oncol.; 2006, 24:4441-4447.
3. Antony S., Jayaraman M., Laco G., et al. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ- III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res.; 2003, 63:7428-7435.
4. Antony S., Agama K.K., Miao Z.H., et al. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11diketo- 11H-indeno{1,2-}isoquinoline)-6-propylamino} propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol. 2006, 70:1109-1120.
5. Arimondo P.B., Bailly C., Boutorine A., et al. Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin. C. R. Acad. Sci. III 1999, 322:785-790.
6. Arimondo P.B., Bailly C., Boutorine A. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase Imediated DNA cleavage to a specific site. Bioconj. Chem. 2001, 12:501-509.
7. Arimondo P.B., Bailly C., Boutorine A.S. Directing topoisomerase I mediated DNA cleavage to specific sites by camptothecin tethered to minor- and major-groove ligands. Angew. Chem. Intl Ed. Engl. 2001, 40:3045-3048.
8. Arimondo P.B., Boutorine A., Baldeyrou B. Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I. J. Biol. Chem.; 2002, 277:3132-3140.
9. Arimondo P.B., Angenault S., Halby L. Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin- oligonucleotide conjugates. Nucleic Acids Res. 2003, 31:4031-4040.
10. Arimondo P.B., Laco G.S., Thomas C.J. Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides. Biochemistry 2005, 44:4171-4180.
11. Arimondo P.B., Thomas C.J., Oussedik K. Exploring the cellular activity of camptothecin- triple-helix-forming oligonucleotide conjugates. Mol. Cell.; Biol. 2006, 26:324-333.
12. Arnaudeau C., Lundin C., Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 2001, 307:1235-1245.
13. Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anti-Cancer drugs. Crit. Rev. Oncol. Hematol. 2003, 45:91-108.
14. Bailly C. Lamellarins, from A to Z: a family of antiCancer marine pyrrole alkaloids. Curr. Med. Chem. AntiCancer Agents 2004, 4:363-378.
15. Bailly C., Lansiaux A., Dassonneville L., et al. Homocamptothecin, an E-ring modifi ed camptothecin analog, generates new topoisomerase Imediated DNA breaks. Biochemistry 1999, 38:15,556-15,563.
16. Beretta G.L., Perego P., Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem. 2006, 13:3291-3305.
17. Beretta G.L., Petrangolini G., de Cesare M., et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer Res. 2006, 66:10,976-10,982.
18. Bhatt R., de Vries P., Tulinsky J. Synthesis and in vivo anti-tumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem.; 2003, 46:190-193.
19. Bhonde M.R., Hanski M.L., Notter M. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumor growth. Oncogene; 2006, 25:165-175.
20. Bielawski K., Winnicka K., Bielawska A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast Cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull. 2006, 29:1493-1497.
21. Bhonde M.R., Hanski M.L., Budczies J. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis. J. Biol. Chem.; 2006, 281:8675-8685.
22. Binaschi M., Parlani M., Bellarosa D. Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate. AntiCancer Drugs 2006, 17:1119-1126.
23. Bom D., Curran D.P., Chavan A.J. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J. Med. Chem.; 1999, 42:3018-3022.
24. Bowman K.J., Newell D.R., Calvert A.H., Curtin N.J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer 2001, 84:106-112.
25. Brunet A., Sweeney L.B., Sturgill J.F. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science; 2004, 303:2011-2015.
26. Burris H.A., Rivkin S., Reynolds R. Phase II trial of oral rubitecan in previously treated pancreatic Cancer patients. Oncologist 2005, 10:183-190.
27. Cagir A., Jones S.H., Eisenhauer B.M. Synthesis and biochemical properties of E-ring modified luotonin A derivatives. Bioorg. Med. Chem.; Lett.; 2004, 14:2051-2054.
28. Catley L., Tai Y.T., Shringarpure R. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res.; 2004, 64:8746-8753.
29. Chatterjee A., Digumarti R., Mamidi R.N. Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory Cancer patients in a Phase I dose escalation study. J. Clin. Pharmacol. 2004, 44:723-736.
30. Chatterjee A., Digumarti R., Katneni K. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory Cancer patients in a bridging Phase I study. J. Clin. Pharmacol. 2005, 45:453-460.
31. Chauvier D., Chourpa I., Bigg D.C.H., Manfait M. Kinetics of in vitro hydrolysis of homocamptothecins as measured by fl uorescence. Ann. NY Acad. Sci.; 2000, 922:314-316.
32. Cheng K., Rahier N.J., Eisenhauer B.M. 14-Azacamptothecin: a potent water-soluble topoisomerase I poison. J. Am. Chem. Soc.; 2005, 127:838-839.
33. Chrencik J.E., Staker B.L., Burgin A.B., Pourquier P., Pommier Y., Stewart L., Redinbo M.R. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J. Mol. Biol. 2004, 339:773-784.
34. Croce A.C., Bottiroli G., Supino R. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol. 2004, 67:1035-1045.
35. Crul M. CKD-602. Chong Kun Dang. Curr. Opin. Invest. Drug 2003, 4:1455-1459.
36. Cusack J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res.; 2001, 61:3535-3540.
37. Dallavalle S., Giannini G., Alloatti D. Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J. Med. Chem.; 2006, 49:5177-5186.
38. d'Amours D., Desnoyers S., d'Silva I., Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 1999, 342:249-268.
39. Dark G.G., Calvert A.H., Grimshaw R. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian Cancer: a trial of the national Cancer institute of Canada clinical trials group. J. Clin. Oncol.; 2005, 23:1859-1866.
40. Daud A., Valkov N., Centeno B. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin. Cancer Res.; 2005, 11:3009-3016.
41. Davies S.M., Harris A.L., Hickson I.D. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant. Nucleic Acids Res. 1989, 17:1337-1351.
42. de Cesare M., Pratesi G., Veneroni S. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin. Cancer Res.; 2004, 10:7357-7364.
43. de Cesare M., Beretta G.L., Tinelli S. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol. 2006, 73:656-664.
44. Demarquay D., Huchet M., Coulomb H. The homocamptothecin BN809l5 is a highly potent orally active topoisomerase I poison. AntiCancer Drugs 2001, 12:9-19.
45. Demarquay D., Huchet M., Coulomb H. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res.; 2004, 64:4942-4949.
46. Dervan P.B., Edelson B.S. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr. Opin. Struct. Biol. 2003, 13:284-299.
47. Desai S.D., Liu L.F., Vazquez-Abad D., d'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the anti-tumor drug camptothecin. J. Biol. Chem. 1997, 272:24,159-24,164.
48. Du W., Curran D.P., Bevins R.L. Synthesis and evaluation of a novel E-ring modifi ed alpha-hydroxy keto ether analogue of camptothecin. Bioorg. Med. Chem.; 2002, 10:103-110.
49. Duffaud F., Borner M., Chollet P., et al. Phase II study of OSI211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur. J. Cancer 2004, 40:2748-2752. and the EORTC-New Drug Development Group/New Drug Development Program.
50. Ejima A., Terasawa H., Sugimori M., et al. Synthesis and anti-leukemic activity of (9/)-20-deoxyaminocamptothecin analogues. Chem. Pharm. Bull. 1989, 37:2253-2255. Tokyo.
51. Ejima A., Terasawa H., Sugimori M., et al. Anti-tumor agents. V. Synthesis and anti-leukemic activity of E-ring-modified (RS)-camptothecin analogues. Chem. Pharm. Bull. 1992, 40:683-688. Tokyo.
52. Elban M.A., Sun W., Eisenhauer B.M. Synthesis and biological evaluation of 10,11-methylenedioxy-14-azacamptothecin. Org. Lett. 2006, 8:3513-3516.
53. Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 1988, 34:755-760.
54. Facompré M., Tardy C., Bal-Mahieu C., et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res. 2003, 63:7392-7399.
55. Fassberg J., Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992, 81:676-684.
56. Fuchs C., Mitchell E.P., Hoff P.M. Irinotecan in the treatment of colorectal Cancer. Cancer Treat. Rev. 2006, 32:491-503.
57. Fujita F., Koike M., Fujita M. MEN4901/ T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent anti-tumor activities in a panel of human tumor xenografts in nude mice. Clin. Cancer Res. 2005, 11:1650-1657.
58. Furuta T., Hayward R.L., Meng L.H. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 2006, 25:2839-2849.
59. Fusaro G., Wang S., Chellappan S. Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene 2002, 21:4539-4548.
60. Fusaro G., Dasgupta P., Rastogi S., et al. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J. Biol. Chem. 2003, 278:47,853-47,861.
61. Gao H., Zhang X., Chen Y. Synthesis and anti-tumor activity of the hexacyclic camptothecin derivatives. Bioorg. Med. Chem.; Lett. 2005, 15:3233-3236.
62. Gatz S.A., Wiesmuller L. p53 in recombination and repair. Cell Death Diff. 2006, 13:1003-1016.
63. Gelderblom H., Salazar R., Verweij J. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ringmodified camptothecin analogue in adults with solid tumors. Clin. Cancer Res. 2003, 9:4101-4107.
64. Gilley J., Coffer P.J., Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 2003, 162:613-622.
65. Giovanella B.C., Stehlin J.S., Hinz H.R. Preclinical evaluation of the anti-Cancer activity and toxicity of 9-nitro-20(S)-camptothecin (rubitecan). Intl J. Oncol. 2002, 20:81-88.
66. Gorka M., Godlewski M.M., Gajkowska B. Kinetics of Smac/DIABLO release from mitochondria during apoptosis of MCF-7 breast Cancer cells. Cell Biol. Intl 2004, 28:741-754.
67. Govindachari T.R., Ravindranath K.R., Viswanathan N. Mappicine, a minor alkaloid from Mappia foetida Miers. J. Chem. Soc. Perkin Trans. 1974, 11:1215-1217.
68. Guo J., Verma U.N., Gaynor R.B. Enhanced chemosensitivity to irinotecan by RNA interferencemediated down-regulation of the nuclear factorkappaB p65 subunit. Clin. Cancer Res. 2004, 10:3333-3341.
69. Hautefaye P., Cimetière B., É A., et al. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg. Med. Chem.; Lett. 2003, 13:2731-2735.
70. Henne W.A., Doorneweerd D.D., Hilgenbrink A.R. Synthesis and activity of a folate peptide camptothecin pro-drug. Bioorg. Med. Chem.; Lett. 2006, 16:5350-5355.
71. Hertzberg R.P., Caranfa M.J., Holden K.G. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32:715-720.
72. Hochberg F., Grossman S.A., Mikkelsen T. Lack of efficacy of 9-aminocamptothecin in patients with newly diagnosed glioblastoma multiforma and recurrent high-grade astrocytoma. Neuro-Oncol. 2002, 2:29-33.
73. Hochster H., Plimack E.R., Runowicz C.D. Biweekly 72-h 9-aminocamptothecin infusion as second- line therapy for ovarian carcinoma: Phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2004, 22:120-126.
74. Horie K., Tomida A., Sugimoto Y. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene 2002, 21:7913-7922.
75. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260:14,873-14,878.
76. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49:5077-5082.
77. Huang H., Regan K.M., Lou Z., et al. CDK2dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006, 314:294-297.
78. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal Cancer. N. Engl. J. Med. 2004, 350:2335-2342.
79. Iyer L., King C.D., Whitington P.F. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 1998, 101:847-854.
80. Jaxel C., Kohn K.W., Wani M.C. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to anti-tumor activity. Cancer Res. 1989, 49:1465-1469.
81. Jaxel C., Capranico G., Kerrigan D., et al. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266:20,418-20,423.
82. Jew S.S., Kim H.J., Kim M.G. Synthesis and anti-tumor activity of 7-substituted 20(RS)-camptothecin analogues. Bioorg. Med. Chem. Lett. 1996, 6:845-848.
83. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by Cancer chemotherapy. Exper. Cell Res. 2000, 256:42-49.
84. Kawato Y., Aonuma M., Hirota Y. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11. Cancer Res. 1991, 51:4187-4191.
85. Kingsbury W.D., Boehm J.C., Jakas D.R. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 1991, 34:98-107.
86. Kluza J., Gallego M.A., Loyens A., et al. Cancer cell mitochondria are direct pro-apoptotic targets for the marine anti-tumor drug lamellarin D. Cancer Res. 2006, 66:3177-3187.
87. Kumazawa E., Ochi Y. DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent anti-tumor activities in various murine tumor models. Cancer Sci. 2004, 95:168-175.
88. Lad T., Rosen F., Sciortino D., et al. Phase II trial of 9-aminocamptothecin in patients with advanced squamous cell head and neck. Cancer. Invest. New Drugs 2000, 18:261-263.
89. Lansiaux A., Facompré M., Wattez N., et al. Apoptosis induced by the homocamptothecin antiCancer drug BN80915 in HL-60 cells. Mol. Pharmacol. 2001, 60:450-461.
90. Lavergne O., Lesueur-Ginot L., Pla Rodas F., Bigg D.C.H. BN80245: an E-ring modifi ed camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. 1997, 7:2235-2238.
91. Lavergne O., Harnett J., Rolland A. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg. Med. Chem.; Lett. 1999, 9:2599-2602.
92. Lavergne O., Lesueur-Ginot L., Pla Rodas F. Homocamptothecins: synthesis and anti-tumor activity of novel E-ring modifi ed camptothecin analogues. J. Med. Chem. 1998, 41:5410-5419.
93. Lawson K.A., Anderson K., Snyder R.M., et al. Novel vitamin E analogue and 9-nitrocamptothecin administered as liposome aerosols decrease syngenic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother. Pharmacol. 2004, 54:421-431.
94. Legarza K., Yang L.X. New molecular mechanisms of action of camptothecin-type drugs. AntiCancer Res. 2006, 26:3301-3305.
95. Lesueur-Ginot L., Demarquay D., Kiss R. Homocamptothecin, an E-ring modifi ed camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and anti-tumor properties. Cancer Res. 1999, 59:2939-2943.
96. Li Q., Zu Y., Shi R. Synthesis and antitumor activity of novel 10-substituted camptothecin analogues. Bioorg. Med. Chem. 2006, 14:7175-7182.
97. Q.Y.Li, Zu Y.G., Shi R.Z., Yao L.P. Review camptothecin: current perspectives. Curr. Med. Chem. 2006, 13:2021-2039.
98. Li T.K., Houghton P.J., Desai S.D. Characterization of ARC-111 as a novel topoisomerase I-targeting anti-Cancer drug. Cancer Res. 2003, 63:8400-8407.
99. Lorence A., Nessler C.L. Camptothecin, over four decades of surprising findings. Phytochem. 2004, 65:2735-2749.
100. Luo P., He Q., He X. Potent anti-tumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer Ther. 2006, 5:962-968.
101. Malanga M., Althaus F.R. Poly(ADPribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J. Biol. Chem. 2004, 279:5244-5248.
102. Marchand C., Antony S., Kohn K.W. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 2006, 5:287-295.
103. Marco E., Laine W., Tardy C. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure activity relationships. J. Med. Chem. 2005, 48:3796-3807.
104. Masubuchi N. Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice. Pharmazie 2004, 59:374-377.
105. Matteucci M., Lin K.Y., Huang T. Sequence specific targeting of duplex DNA using a camptothecin-triple helix forming oligonucleotide conjugate and topoisomerase I. J. Am. Chem. Soc. 1997, 119:6939-6940.
106. Megonigal M.D., Cheung N.K., Rappaport E.F., et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl Acad. Sci. USA 2000, 97:2814-2819.
107. Mesner P.W., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv. Pharmacol. 1997, 41:461-499.
108. Mi Z., Malak H., Burke T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995, 34:13,722-13,728.
109. Micheau O., Solary E., Hammann A., et al. Sensitization of Cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl Cancer Inst. 1997, 89:783-789.
110. Mihara M., Erster S., Zaika A. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 2003, 11:577-590.
111. Miknyoczki S.J., Jones-Bolin S., Pritchard S. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2003, 2:371-382.
112. Miller A.A., Herndon J.E., Gub L., Green M.R. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung Cancer (CALGB 30004). Lung Cancer 2005, 48:399-407.
113. Miller D.S., Blessing J.A., Waggoner S. Phase II evaluation of 9-aminocamptothecin (9- AC, NSC 603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2005, 96:67-71.
114. Mitsui I., Kumazawa E., Hirota Y. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent anti-tumor activity against human tumors in vitro and in vivo. Jpn J. Cancer Res. 1995, 86:776-782.
115. Mo Y.Y., Yu Y., Shen Z., Beck W.T. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 2002, 277:2958-2964.
116. Moertel C.G., Schutt A.J., Reitemeier R.J., Hahn R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal Cancer. Cancer Chemother. Rep. 1972, 56:95-101.
117. Morrell A., Antony S., Kohlhagen G. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J. Med. Chem. 2006, 49:7740-7753.
118. Morris E.J., Geller H.M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 1996, 134:757-770.
119. Muggia F.M., Creaven P.J., Hansen H.H. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 1972, 56:515-521.
120. Nagarajan M., Morrell A., Antony S. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J. Med. Chem. 2006, 49:5129-5140.
121. Nagarajan M., Morrell A., Ioanoviciu A. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J. Med. Chem. 2006, 49:6283-6289.
122. Nicholas A.W., Wani M.C., Manikumar G. Plant anti-tumor agents. 29, Synthesis and biological activity of ring D and ring E modified analogues of camptothecin. J. Med. Chem. 1990, 33:972-978.
123. Nitiss J.L., Nitiss K.C. Gimatecan (sigmatau industrie farmaceutiche riunite/novartis). IDrugs 2005, 8:578-588.
124. Nitiss J.L., Wang J.C. DNA topoisomerasetargeting anti-tumor drugs can be studied in yeast. Proc. Natl Acad. Sci. USA 1988, 85:7501-7505.
125. Ochi Y., Shiose Y., Kumazawa E. A possible mechanism for the long-lasting anti-tumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother. Pharmacol. 2005, 55:323-332.
126. Onishi H., Machida Y. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. Curr. Drug Discov. Technol. 2005, 1:169-183.
127. Owen O.G. Exatecan and gemcitabine: no better than gemcitabine only. Lancet Oncol. 2006, 7:891.
128. Paquet C., Sane A.T., Beauchemin M., Bertrand R. Caspase- and mitochondrial dysfunctiondependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 2005, 19:784-791.
129. Pazdur R., Diaz-Canton E., Ballard W.P. Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma. J. Clin. Oncol. 1997, 15:2905-2909.
130. Pazdur R., Medgyesy D.C., Winn R.J., et al. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-h continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest. New Drugs 1999, 16:341-346.
131. Philippart P., Harper L., Chaboteaux C. Homocamptothecin, an E-ring-modifi ed camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon Cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin. Cancer Res. 2000, 6:1557-1562.
132. Piret B., Piette J. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH2 and CEM cells. Nucleic Acids Res. 1996, 24:4242-4248.
133. Pitot H.C., Knost J.A., Mahoney M.R., et al. A north central Cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer 2000, 89:1699-1705.
134. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Natl Rev. Cancer 2006, 6:789-802.
135. Pommier Y., Poddevin B., Gupta M., Jenkins J. DNA topoisomerases I & II cleavage sites in the type 1 human immunodeficiency virus (HIV-1) DNA promoter region. Biochem. Biophys. Res. Commun. 1994, 205:1601-1609.
136. Pommier Y., Redon C., Rao V.A. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res. 2003, 532:173-203.
137. Posey J.A., Saif M.W., Carlisle R., et al. Phase I study of weekly polyethylene glycol- camptothecin in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 2005, 11:7866-7871.
138. Potmesil M., Arbuck S.G., Takimoto C.H. 9-Aminocamptothecin and beyond. Preclinical and clinical studies. Ann. NY Acad. Sci. 1996, 803:231-246.
139. Pratesi G., de Cesare M., Carenini N. Pattern of anti-tumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin. Cancer Res. 2002, 8:3904-3909.
140. Prudhomme M. Rebeccamycin analogues as anti-Cancer agents. Eur. J. Med. Chem. 2003, 38:123-140.
141. Rahier N.J., Cheng J.C., Gao R. Synthesis of 14-azacamptothecin, a water-soluble topoisomerase I poison. Org. Lett. 2005, 7:835-837.
142. Rastogi S., Joshi B., Fusaro G., Chellappan S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J. Biol. Chem. 2006, 281:2951-2959.
143. Ray S., Almasan A. Apoptosis induction in prostate Cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor- related apoptosis-inducing ligand and CPT-11. Cancer Res. 2003, 63:4713-4723.
144. Redinbo M.R., Stewart L., Kuhn P. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998, 279:1504-1513.
145. Rodriguez-Hernandez A., Brea-Calvo G., Fernandez-Ayala D.J. Nuclear caspase-3 and caspase- 7 activation, and Poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis. Apoptosis 2006, 11:131-139.
146. Saltz L.B., Kemeny N.E., Tong W. 9- Aminocamptothecin by 72-h continuous intravenous infusion is inactive in the treatment of patients with 5-fl uorouracil-refractory colorectal carcinoma. Cancer 2000, 80:1727-1732.
147. Sanchez-Alcazar J.A., Ault J.G., Khodjakov A., Schneider E. Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells. Cell Death. Diff. 2000, 7:1090-1100.
148. Schluep T., Hwang J., Cheng J. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple Cancer models. Clin. Cancer Res. 2006, 12:1606-1614.
149. Seiden M.V., Muggia F., Astrow A. A Phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian Cancer. Gynecol. Oncol. 2004, 93:229-232.
150. Seiter K. Toxicity of the topoisomerase I inhibitors. Expert Opin. Drug Safety 2005, 4:45-53.
151. Shao R.G., Cao C.X., Zhang H. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 1999, 18:1397-1406.
152. Smith L.M., Willmore E., Austin C.A., Curtin N.J. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 2005, 11:8449-8457.
153. Snyder L., Shen W., Bornmann W.G., Danishefsky S.J. Synthesis of 18-nonanhydrocamptothecin analogs which retain topoisomerase I inhibitory function. J. Org. Chem. 1994, 59:7033-7037.
154. Staker B.L., Hjerrild K., Feese M.D., et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA. Proc. Natl. Acad. Sci. USA. Proc. Natl. Acad. Sci. USA 2002, 99:392-415.
155. Staker B.L., Feese M.D., Cushman M. Structures of three classes of anti-Cancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 2005, 48:2336-2345.
156. Subrahmanyam D., Venkateswarlu A., Venkateswara Rao K. In vitro cytotoxicity of 5-aminosubstituted 20(S)-camptothecins. Part 1. Bioorg. Med. Chem.; Lett. 1999, 9:1633-1638.
157. Sugimori M., Ejima A., Ohsuki S. Antitumor agents. 7. Synthesis and anti-tumor activity of novel hexacyclic camptothecin analogues. J. Med. Chem. 1994, 37:3033-3039.
158. Sugimori M., Ejima A., Ohsuki S. Synthesis and anti-tumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J. Med. Chem. 1998, 41:2308-2318.
159. Sun L.C., Luo J., Mackey L.V. A conjugate of camptothecin and a somatostatin analog against prostate Cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alpha V-beta3/ alpha Vbeta5 and MMP-2/-9. Cancer Lett 2007, 246:157-166.
160. Tangirala R.S., Antony S., Agama K. Synthesis and biological assays of E-ring analogs of camptothecin and homocamptothecin. Bioorg. Med. Chem. 2006, 14:6202-6212.
161. Tentori L., Leonetti C., Scarsella M. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 2006, 20:1709-1711.
162. Thomas C.J., Rahier N.J., Hecht S.M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12:1585-1604.
163. Tonini T., Gabellini C., Bagella L. pRb2/ p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin. Cancer Res. 2004, 10:8085-8093.
164. Troconiz I.F., Garrido M.J., Segura C. Phase I dose-finding study and a pharmacokinetic/ pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumors. Cancer Chemother. Pharmacol. 2006, 57:727-735.
165. Urnov F.D., Miller J., Lee Y.-L. Highly efficient endogenous human gene correction using designed zinc-fi nger nucleases. Nature 2005, 435:646-651.
166. Vokes E.E., Gordon G.S., Rudin C.M. A Phase II trial of 9-aminocamptothecin as a 120-h infusion in patients with non-small cell lung Cancer. Invest. New Drugs 2001, 19:329-333.
167. Wadkins R.M., Bearss D., Manikumar G. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res. 2004, 64:6679-6683.
168. Wadkins R.M., Bearss D., Manikumar G. Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity. Curr. Med. Chem. Anti-Cancer Agents 2004, 4:327-334.
169. Wall M.E., Wani M.C., Cook C.E., et al. Plant anti-tumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88:3888-3890.
170. Walton M.I., Whysong D., O'Connor P.M., et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993, 53:1853-1861.
171. Wang C.C., Dervan P.B. Sequence-specific trapping of topoisomerase I by DNA binding polyamide-camptothecin conjugates. J. Am. Chem. Soc. 2001, 123:8657-8661.
172. Wang C.Y., Mayo M.W., Korneluk R.G. NF-kappaB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase8 activation. Science 1998, 281:1680-1683.
173. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65:635-692.
174. Wang S., Nath N., Adlam M., Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999, 18:3501-3510.
175. Wang X., Zhou X., Hecht S.M. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 1999, 38:4374-4381.
176. Wani M.C., Nicholas A.W., Wall M.E. Plant anti-tumor agents. 23. Synthesis and anti-leukemic activity of campothecin analogues. J. Med. Chem. 1986, 29:2358-2363.
177. Whitmarsh R.J., Saginario C., Zhuo Y. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 2003, 22:8448-8459.
178. Wu J., Yin M.B., Hapke G. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol. Pharmacol. 2002, 61:742-748.
179. Xiao X., Cushman M. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment. J. Org. Chem. 2005, 70:9584-9587.
180. Xiao X., Miao Z.H., Antony S. Dihydroin denoisoquinolines function as pro-drugs of indenoisoquinolines. Bioorg. Med. Chem.; Lett. 2005, 15:2795-2798.
181. Xiao X., Antony S., Pommier Y., Cushman M. Total synthesis and biological evaluation of 22-hydroxyacuminatine. J. Med. Chem. 2006, 49:1408-1412.
182. Xie G., Gupta R., Atchison K., Lown J.W. Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation. J. Med. Chem. 1996, 39:1049-1055.
183. Xu M.L., Li G., Moon D.C. Cytotoxicity and DNA topoisomerase inhibitory activity of constituents isolated from the fruits of Evodia officinalis. Arch. Pharm. Res. 2006, 29:541-547.
184. Yaegashi T., Sawada S., Nagata H. Synthesis and anti-tumor activity of 20(S)-camptothecin derivatives. A-ring-substituted 7-ethylcamptothecins and their E-ring-modifi ed water-soluble derivatives.. Chem. Pharm. Bull. (Tokyo) 1994, 42:2518-2525.
185. Yang D., Strode J.T., Spielman H.P. DNA interaction of two clinical camptothecin drugs stabilize their active lactone forms. J. Am. Chem. Soc. 1998, 120:2979-2980.
186. Yoshinari T., Ohkubo M., Fukasawa K. Mode of action of a new indolocarbazole anti-Cancer agent, J-107088, targeting topoisomerase I. Cancer Res. 1999, 59:4271-4275.
187. Yu D., Khan E., Khaleque M.A., et al. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J. Biol. Chem.. J. Biol. Chem.. J. Biol. Chem. 2004, 279:861-951.
188. Yu J., Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 2005, 331:851-858.
189. Zhao R., al-Said N.H., Sternbach D.L., Lown J.W. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anti-Cancer cytotoxicity in vitro. J. Med. Chem. 1997, 40:216-225.